pp-019 Tablets, extended release (ER)
Dossier type
CTD
Dossier status
Ready to file
Country of origin
China
Registered in
China
Comments
SGLT2/Metformin combination. Same class molecules: Dapagliflozin and Metformin, Empagliflozin and Metformin
Manufacturer #17216
Global developer of innovative drugs in oncology, metabolic, autoimmune, and cardiovascular diseases, with 14 in-house products and multiple partnerships. Over 5,000 R&D staff across global centers and strong IP, clinical pipeline, and high-standard manufacturing.
Manufacturer usually replies in 41 days